Figure 5.

This includes the VENN diagrams for the proteins found to be significantly higher or lower in the EVs of the CKD patients and the post-transplant CKD patients (each group compared to the plasma proteins of the healthy controls). Of those proteins, 18 were found to be shared as they were significantly higher in both the CKD patients and the post-transplant CKD patients. Of note, the red font was used to indicate the proteins that were higher in CKD or in post-transplant CKD (vs. healthy). The blue font was used to denote the proteins that were lower in CKD or post-transplant CKD (vs. healthy controls). The arrows denote that there are additional proteins not shown in the figure. For a complete list of the proteins that differed significantly between CKD and healthy controls or post-transplant CKD and healthy controls, refer to supplemental Tables 2S and 3S, respectively. ABV: COL18: collagen 18, TIMP-1: tissue inhibitor of metalloproteinases, PRSS: serine protease, RARRES-2: retinoic acid receptor responder protein 2, UNC5C: Unc-5 Netrin Receptor C, SLP1: secretory leukocyte protease inhibitor, CCL14: C–C Motif Chemokine Ligand 14, TNFRSF1A: tumor necrosis factor receptor superfamily member 1A, RTN4R: Reticulon 4 Receptor, CTSH: cathepsin H, MAP2K: mitogen-activated protein kinase kinase, CXCL16: Chemokine (C-X-C motif) ligand 16, CCDC80: coiled-coil domain containing 80, TSPB2: tryptase beta-2, IL12B IL23A: reactome with interleukin-12B and interleukin-23A, REN: renin precursor, ERp29: endoplasmic reticulum protein 29, CCL15: Chemokine Ligand 15, TNFRSF1B: tumor necrosis factor receptor superfamily member 1B, MAPK: mitogen-activated protein kinase, CGA FSH-β: chorionic gonadotropin follicle-stimulating hormone-β, ADIPOQ: Adiponectin, C1Q And Collagen Domain Containing, ESAM: endothelial cell-selective adhesion molecule, MET: tyrosine-protein kinase Met, NME: Nucleoside Diphosphate Kinase, CFB: complement factor B, KIT: tyrosine-protein kinase kit.